VIBRANT: VIB4920 for Active Lupus Nephritis

This is a multi-center double-blind placebo controlled clinical trial evaluating the efficacy of VIB4920 combined with mycophenolate mofetil (MMF) and prednisone in achieving a renal response in participants with active lupus nephritis (LN). Eligible participants with active lupus nephritis (LN) will receive induction therapy with mycophenolate mofetil (MMF), methylprednisolone and prednisone. Participants will be assessed at Week 8 for a renal response. Participants who are not eligible for randomization will complete study participation after the Week 8 study visit, and further care will be provided according to the judgment of the site investigator or treating physician.

If you meet the study requirements and are enrolled, you will be in this study for about 60 weeks.